| Fiscal period | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Period End Date | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 |
|---|
| Net Sales | 6,939.90 | 6,827.30 | 6,127.50 | 7,982.20 | 7,932.90 | 7,803.30 | 7,668.40 | 5,997.80 | 4,673.30 | 4,623.40 |
| Total Revenues | 6,939.90 | 6,827.30 | 6,127.50 | 7,982.20 | 7,932.90 | 7,803.30 | 7,668.40 | 5,997.80 | 4,673.30 | 4,623.40 |
| Cost of Products Sold | 2,019.50 | 1,960.40 | 1,824.30 | 2,252.60 | 2,271.90 | 2,132.90 | 2,381.80 | 1,800.60 | 1,242.80 | 1,266.70 |
| Gross Profit | -- | -- | -- | -- | -- | -- | 5,286.60 | 4,197.20 | 3,430.50 | 3,356.70 |
| Goodwill impairment | 292.80 | 16.30 | 503.00 | 70.10 | 979.70 | 331.50 | 31.10 | -- | -- | -- |
| Intangible asset amortization | 526.80 | 529.50 | 512.10 | 584.30 | 595.90 | 603.90 | 565.90 | 337.40 | 92.50 | 78.50 |
| Research and development | 406.00 | 435.80 | 322.80 | 449.30 | 391.70 | 369.90 | 365.60 | 268.80 | 187.40 | 203.00 |
| In-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative | 2,761.70 | 2,843.40 | 2,712.70 | 3,343.80 | 3,379.30 | 3,104.70 | 2,944.60 | 2,284.20 | 1,750.70 | 1,749.30 |
| Acquisition, integration and other expense | 11.40 | 3.10 | 11.40 | 12.20 | 99.50 | 262.20 | 504.90 | -- | -- | -- |
| Restructuring and other cost reduction initiatives | 191.60 | 125.70 | 107.20 | 50.00 | 34.20 | 17.60 | -- | -- | -- | -- |
| Special items | -- | -- | -- | -- | -- | -- | -- | (839.50) | (341.10) | (210.30) |
| Settlement | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Certain claims | -- | -- | -- | -- | -- | -- | -- | -- | (21.50) | (47.00) |
| Net curtailment and settlement | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Quality remediation | (33.80) | (52.80) | (50.90) | (82.40) | (146.90) | (181.30) | (53.40) | -- | -- | -- |
| Operating Expenses | 6,243.60 | 5,967.00 | 6,044.40 | 6,844.70 | 7,899.10 | 7,004.00 | 6,847.30 | 5,530.50 | 3,636.00 | 3,554.80 |
| Operating Income (Loss) | 696.30 | 860.30 | 83.10 | 1,137.50 | 33.80 | 799.30 | 821.10 | 467.30 | 1,037.30 | 1,068.60 |
| Interest expense, net | 164.80 | 208.40 | 212.10 | 226.90 | 289.30 | 325.30 | 355.00 | 286.60 | 63.10 | 70.10 |
| Interest income (expense) | -- | -- | -- | -- | -- | -- | -- | 9.40 | 11.90 | 15.60 |
| Loss on early extinguishment of debt | -- | (165.10) | -- | -- | -- | -- | -- | -- | -- | -- |
| Other expense | (128.00) | 12.20 | 23.80 | (4.80) | (15.60) | (9.40) | (66.50) | (36.90) | (46.70) | (6.00) |
| Earnings before income taxes and minority interest | 403.50 | 499.00 | (105.20) | 905.80 | (271.10) | 464.60 | 399.60 | 153.20 | 939.40 | 1,008.10 |
| Current Federal | 175.30 | 44.30 | (58.40) | 65.50 | (46.20) | 438.50 | 134.20 | 55.80 | 178.20 | 207.20 |
| Current State | 16.10 | 7.20 | 2.70 | 9.80 | 24.40 | 2.40 | 12.40 | 18.90 | 16.50 | 20.80 |
| Current Foreign | (14.70) | 104.10 | (79.70) | 237.70 | 116.60 | (13.70) | 101.60 | 96.30 | 116.00 | 127.70 |
| Deferred Federal | (74.80) | (83.50) | (12.70) | (90.20) | 37.90 | (1,728.50) | (108.50) | (120.60) | (54.80) | (91.80) |
| Deferred State | 1.60 | (19.40) | (10.00) | (4.20) | (8.80) | (95.50) | 2.30 | (20.00) | (6.60) | (8.40) |
| Deferred Foreign | 8.80 | 0.80 | 62.10 | (444.30) | (15.70) | 48.00 | (47.00) | (23.40) | (29.10) | (26.00) |
| Provision for Income Tax | 112.30 | 53.50 | (96.00) | (225.70) | 108.20 | (1,348.80) | 95.00 | 7.00 | 220.20 | 229.50 |
| Minority interest | 1.00 | 0.50 | 1.50 | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc | 290.20 | 445.00 | (10.70) | -- | -- | -- | -- | -- | -- | -- |
| (Loss) Earnings from discontinued operations, net of taxes | (58.80) | (43.40) | (128.20) | -- | -- | -- | -- | -- | -- | -- |
| Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative Effect of Change in Accounting Principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings | 231.40 | 401.60 | (138.90) | 1,131.50 | (379.30) | 1,813.40 | 304.60 | 146.20 | 719.20 | 778.60 |
| Less : Net earnings attributable to noncontrolling interest | -- | -- | -- | (0.10) | (0.10) | (0.40) | (1.30) | (0.80) | (1.10) | (1.80) |
| Net Income (loss) Available to Common Shareholders | 231.40 | 401.60 | (138.90) | 1,131.60 | (379.20) | 1,813.80 | 305.90 | 147.00 | 720.30 | 780.40 |
| Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings from continuing operations | 1.38 | 2.14 | (0.05) | -- | -- | -- | -- | -- | -- | -- |
| (Loss) earnings from discontinued operations | (0.28) | (0.21) | (0.62) | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of change in accounting principle, net of tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | 1.10 | 1.93 | (0.67) | 5.52 | (1.86) | 8.98 | 1.53 | 0.78 | 4.26 | 4.60 |
| Earnings before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings from continuing operations | 1.38 | 2.12 | (0.05) | -- | -- | -- | -- | -- | -- | -- |
| (Loss) earnings from discontinued operations | (0.28) | (0.21) | (0.62) | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of change in accounting principle, net of tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | 1.10 | 1.91 | (0.67) | 5.47 | (1.86) | 8.90 | 1.51 | 0.77 | 4.20 | 4.54 |
| Weighted Average Shares Outstanding (Basic) | 209.60 | 208.60 | 207.00 | 205.10 | 203.50 | 201.90 | 200.00 | 187.40 | 169.00 | 169.60 |
| Weighted Average Shares Outstanding (Diluted) | 210.30 | 210.40 | 207.00 | 206.70 | 203.50 | 203.70 | 202.40 | 189.80 | 171.70 | 171.80 |